

In the claims

The following amendments are made with respect to the claims in the international application PCT/GB03/03720.

This listing of claims will replace all prior versions and listings of claims in this application.

1-15 (Cancelled).

16 (New). A method for the treatment of a condition selected from the group consisting of obesity and weight gain; substance abuse and drug addiction; smoking cessation; eating disorders, and obsessive-compulsive disorder; wherein the treatment comprises administering, to an individual in need of such treatment, (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof.

17 (New). The method, according to claim 16, wherein said condition is obesity and weight gain.

18 (New). The method, according to claim 16, wherein said condition is substance abuse and drug addiction.

19 (New). The method, according to claim 16, wherein smoking cessation is desired.

20 (New). The method, according to claim 16, wherein said condition is an eating disorder.

21 (New). The method, according to claim 16, wherein said condition is obsessive-compulsive disorder.

22 (New). The method, according to claim 16, wherein the salt is the hydrochloride monohydrate.

23 (New). A method for the treatment of a condition selected from the group consisting of pre-menstrual syndrome; migraine; nausea and vomiting; chemotherapy or radioactivity-induced emesis; and fatigue; wherein the treatment comprises, administering to an individual in need of such treatment, (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof.

24 (New). The method, according to claim 23, wherein said condition is pre-menstrual syndrome.

25 (New). The method, according to claim 23, wherein said condition is migraine.

26 (New). The method, according to claim 23, wherein said condition is nausea and vomiting.

27 (New). The method, according to claim 23, wherein said condition is chemotherapy or radioactivity-induced emesis.

28 (New). The method, according to claim 23, wherein said condition is fatigue.

29 (New). The method, according to claim 23, wherein the salt is the hydrochloride monohydrate.

30 (New). A method for the treatment of a condition selected from the group consisting of fibromyalgia; Parkinson's disease; stroke; and schizophrenia; wherein the treatment comprises administering, to an individual in need of such treatment, (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof.

31 (New). The method, according to claim 30, wherein said condition is fibromyalgia.

32 (New). The method, according to claim 30, wherein said condition is Parkinson's disease.

33 (New). The method, according to claim 30, wherein said condition is a stroke.

34 (New). The method, according to claim 30, wherein said condition is schizophrenia.

35 (New). The method, according to claim 30, wherein the salt is the hydrochloride monohydrate.